- Home
- TXMD vs AIMD Comparison
TXMD vs AIMD Comparison
Compare TXMD & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- AIMD
- Stock Information
- Founded
- TXMD 2008
- AIMD 1984
- Country
- TXMD United States
- AIMD United States
- Employees
- TXMD N/A
- AIMD N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- AIMD Health Care
- Exchange
- TXMD Nasdaq
- AIMD Nasdaq
- Market Cap
- TXMD 13.5M
- AIMD 11.9M
- IPO Year
- TXMD N/A
- AIMD N/A
- Fundamental
- Price
- TXMD $1.17
- AIMD $2.94
- Analyst Decision
- TXMD
- AIMD
- Analyst Count
- TXMD 0
- AIMD 0
- Target Price
- TXMD N/A
- AIMD N/A
- AVG Volume (30 Days)
- TXMD 35.2K
- AIMD 76.6K
- Earning Date
- TXMD 08-11-2025
- AIMD 08-04-2025
- Dividend Yield
- TXMD N/A
- AIMD N/A
- EPS Growth
- TXMD N/A
- AIMD N/A
- EPS
- TXMD N/A
- AIMD N/A
- Revenue
- TXMD $1,841,000.00
- AIMD $106,207.00
- Revenue This Year
- TXMD $427.09
- AIMD N/A
- Revenue Next Year
- TXMD N/A
- AIMD N/A
- P/E Ratio
- TXMD N/A
- AIMD N/A
- Revenue Growth
- TXMD 53.55
- AIMD 13.38
- 52 Week Low
- TXMD $0.70
- AIMD $2.00
- 52 Week High
- TXMD $2.44
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- TXMD 47.76
- AIMD 50.61
- Support Level
- TXMD $1.13
- AIMD $3.07
- Resistance Level
- TXMD $1.24
- AIMD $3.34
- Average True Range (ATR)
- TXMD 0.09
- AIMD 0.24
- MACD
- TXMD 0.01
- AIMD 0.04
- Stochastic Oscillator
- TXMD 73.12
- AIMD 60.37
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.